Bangkok, Aug 5 (TNA) – The Chulabhorn Royal Academy (CRA) and the Faculty of Pharmaceutical Science at Chulalongkorn University introduced Thailand’s first favipiravir syrup for COVID-infected children and patients with swallowing difficulty.

 

CRA secretary-general Prof Dr Nithi Mahanonda said that during the present wave of COVID-19, 10% of patients were children and to survive they would need antiviral drug favipiravir within four days after developing severe symptoms.

 

According to him, Chulabhorn Hospital is capable of producing and distributing favipiravir syrup to about 300 patients per week. 

 

Full Story: https://tna.mcot.net/english-news-752955

 

-- © Copyright TNA 2021-08-05

 

- Whatever you're going through, the Samaritans are here for you

- Follow ASEAN NOW on LINE for breaking COVID-19 updates

ability to treat 300 patients a weeks is a serious help when we have now over 20k daily (over 140k weekly) positives.

This antiviral, as well as all intivirals, suppose to be administered immediately on diagnosis. There is no point waiting for virus to multiply and develop serious state and still wait 4 days after that situation. Too late. 

Call yourself now Joke Academy and Faculty of Pharmaceutical Ignorance.

Why no scale up production 100 000 times and give it to everybody in small doses as preventative? And export it all over the world and finance buying more sinopharm?

As scientists they fail to be creative, imaginative and brave in this dramatic situation. They just thread what they were accustomed through their lives - utter passivity 

Edited August 5, 20214 yr by internationalism

Favipiravir possibly exerted no significant beneficial effect in the term of mortality in the general group of patients with mild to moderate COVID-19. We should consider that perhaps the use of antiviral once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting.

Stories like this are the result of the publisher telling editors that he's sick of bad news. (The publisher has the regime breathing down his neck).

 

 

6 minutes ago, rotorbreeze said:

Favipiravir possibly exerted no significant beneficial effect in the term of mortality in the general group of patients with mild to moderate COVID-19.

 

Favipiravir is used in both mild cases with patients who have co-morbidities, and severe pneumonia cases.

 

Chloroquine is also used. AS are: Lopinavir/Ritonavir or alternative regimens Darunavir/Ritonavir.

 

 

 

They don't really have an effective treatment, so trotting this out makes them feel like they're doing something (forgetting for a moment who's making money on this scheme), and fools most of the public into thinking they are using "science".

 

 

Did we expect anything different?

 

 

 

 

 

 

14 hours ago, internationalism said:

ability to treat 300 patients a weeks is a serious help when we have now over 20k daily (over 140k weekly) positives.

This antiviral, as well as all intivirals, suppose to be administered immediately on diagnosis. There is no point waiting for virus to multiply and develop serious state and still wait 4 days after that situation. Too late. 

Call yourself now Joke Academy and Faculty of Pharmaceutical Ignorance.

Why no scale up production 100 000 times and give it to everybody in small doses as preventative? And export it all over the world and finance buying more sinopharm?

As scientists they fail to be creative, imaginative and brave in this dramatic situation. They just thread what they were accustomed through their lives - utter passivity 

If you read the article he is referring to children and patients with swallowing difficulties.

There are not 20k of those per day.

20 minutes ago, StevieAus said:

If you read the article he is referring to children and patients with swallowing difficulties.

There are not 20k of those per day.

ok, 10% of infected are children. As many as elderly. So 20% is still 4k patients daily which would potentially benefit

6 hours ago, rotorbreeze said:

Favipiravir possibly exerted no significant beneficial effect in the term of mortality in the general group of patients with mild to moderate COVID-19. We should consider that perhaps the use of antiviral once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting.

I don't understand. If it's mild to moderate Covid-19, wouldn't mortality in that group be zero? Anyone who dies, by definition, didn't have a mild or moderate case. 

If there any evidence that it works?  I haven't seen any.